# A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC

> **NCT07178795** · PHASE3 · RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 440 (estimated)

## Conditions studied

- Non-squamous Non-small Cell Lung Cancer

## Interventions

- **DRUG:** BL-M07D1
- **DRUG:** Pembrolizumab
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT07178795
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-29
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 440 (ESTIMATED)
- **Last updated:** 2025-11-17

## Collaborators

- Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07178795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07178795, "A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07178795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*